AssetMark Inc
ANIP icon

AssetMark Inc’s ANI Pharmaceuticals ANIP Stock Holding History

AssetMark Inc’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$911 Hold
11
– – ﹤0.01% 3167
2026
Q1 		$846 Buy
+11
New +$859 ﹤0.01% 3071
2018
Q1 		– Sell
-12
Closed -$1K – 1427
2017
Q4 		$1K Buy
+12
New +$747 ﹤0.01% 1545

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AssetMark Inc's ANIP Position: Q2 2026 in Review

AssetMark Inc held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 11 shares worth $911. The position accounts for ﹤0.01% of the portfolio, ranked #3167.

AssetMark Inc first reported a position in ANIP in Q4 2017 and has held it in 3 quarters since. The position peaked at $1K in Q4 2017. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • AssetMark Inc held 11 shares of ANI Pharmaceuticals worth $911 as of Q2 2026.
  • AssetMark Inc left its ANI Pharmaceuticals share count unchanged in Q2 2026.
  • ANI Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3167 holding.
  • AssetMark Inc first reported a position in ANI Pharmaceuticals in Q4 2017 and has held it in 3 quarters since.
  • AssetMark Inc's ANI Pharmaceuticals position peaked at $1K in Q4 2017.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.